China, AstraZeneca
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
Guggenheim adjusted its price target on shares of AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), increasing it to GBP13,100 from ...
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
AstraZeneca PLC AZN shares inched up 0.87% to £109.38 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 1.35% to 8,505.22.
Guggenheim raised the firm’s price target on AstraZeneca (AZN) to 13,100 GBp from 12,600 GBp and keeps a Buy rating on the shares. The firm is ...
News Medical on MSN2d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina MakerMina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.Cho0xxI9.js ...
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback